Published on 18/03/2015 by admin
Filed under Dermatology
Last modified 18/03/2015
This article have been viewed 2289 times
Amit Garg and Jeffrey D. Bernhard
Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports
Pruritus is a cutaneous sensation (usually unpleasant) that evokes an urge to scratch, rub, pick, and, in extreme cases, mutilate the skin in an attempt to obtain relief. We use the terms itch and pruritus interchangeably. Itch occurs as a characteristic feature of many skin diseases, such as atopic dermatitis and lichen planus. It can also occur as an unusual symptom of systemic disorders, such as hyperthyroidism, cholestasis, and uremia. Pruritus in the absence of a detectable rash, whether localized or generalized, poses both a diagnostic and a therapeutic challenge to even the most seasoned dermatologist. New findings in the neurophysiology of itch have led to specific therapies that target particular pathways and receptors in the nervous system.
Management of pruritus is directed toward its cause, which may not always be apparent, regardless of whether dermatitis is present. Many dermatoses itch, and it is beyond the scope of this chapter to discuss them all. Xerosis and scabies deserve special mention because both can have subtle findings with intensity of pruritus out of proportion to rash. In xerosis, an adequate skin care regimen and emollients are indispensable. One of the more common and embarrassing errors is to miss the diagnosis of scabies, and consideration of this diagnosis may avoid delays in treatment and undue suffering.
Failure to diagnose a primary skin disease does not rule out the possibility that one is present; time, repeated observation, and laboratory tests such as a skin biopsy may be required. When no rash is present, or when a rash is present but cannot be diagnosed, further evaluation is indicated. The evaluation should include a thorough medical history and physical examination, complete with a precise medication review and review of systems. The physical examination should include palpation for organomegaly and lymphadenopathy. The examiner should not be misled by non-specific secondary changes caused by rubbing, scratching, or secondary infection. A ‘peculiar’ eczematous dermatitis resistant to treatment may be a secondary phenomenon, not necessarily the primary diagnosis. Laboratory investigations are often essential in the clinical assessment of chronic pruritus, whether a rash is present or not. The presence or absence of constitutional signs or symptoms should be determined at the initial and follow-up visits.
The most serious error is to miss the diagnosis of an underlying systemic disease associated with pruritus. Some of the many systemic diseases that may cause pruritus include hematologic and solid malignancies, lymphoproliferative disorders, HIV, thyroid disease, iron deficiency, renal disease, hepatobiliary disease, connective tissue disease, neurologic disease, and drug hypersensitivity. Interval re-evaluation for associated systemic disease should be undertaken since pruritus may precede the diagnosis of a systemic disease by many months (as in primary biliary cirrhosis).
Screening
Complete medical history
Careful medication history
Thorough review of systems
Complete physical exam
Laboratory investigations
Complete blood count with differential
Blood urea nitrogen, creatinine
Fasting glucose
Hepatic function testing
Thyroid function testing
Chest radiograph (posteroanterior and lateral)
Age-appropriate cancer screening
Additional testing to consider
Scraping for scabies
Hepatitis B and C profiles
HIV testing
Erythrocyte sedimentation rate
Serum iron and ferritin
Serum protein electrophoresis, urine protein electrophoresis
Stool for ova and parasites
Anti-mitochondrial antibody test
Skin biopsy
For symptomatic relief, general skin hygiene measures (e.g., moisturization) and elimination of exacerbating factors (e.g., excessively dry air) are worthwhile but rarely sufficient. Tepid water baths using fragrance-free moisturizing soaps, emollients, unscented bath oils applied liberally after bathing, a cool moisture rich environment, and loose fit clothing are helpful. In the management of pruritus that does not respond to simple measures, treatment should be individualized based on etiology, severity, and regard for safety.
Itch and pruritus: what are they and how should itches be classified?
Bernhard JD. Dermatol Ther 2005; 18: 288–91.
Clinical classification of itch: a position paper of the International Forum for the Study of Itch.
Ständer S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, et al. Acta Derm Venereol 2007; 87: 291–4.
These two papers explain the terms used to signify different categories of pruritic disorders.
Neurophysiological and neurochemical basis of modern pruritus treatment.
Ständer S, Weisshaar E, Luger TA. Exp Dermatol 2008; 17: 161–9.
This review highlights modern neurophysiological and neurochemical therapeutic strategies on the basis of neuronal mechanisms underlying chronic pruritus.
Pruritus of undetermined origin.
Yosipovitch G, Bernhard JD. N Engl J Med 2013; 368: 1625–34.
This review describes the evaluation, and symptomatic treatment of patients without a clear diagnosis.
Ultraviolet phototherapy for pruritus.
Rivard J, Lim HW. Dermatolog Ther 2005; 18: 344–54.
Ultraviolet-based therapy is used to treat a variety of pruritic conditions. In this review, mechanisms of action for phototherapy are discussed. Treatment limitations, side effects, and common dosing protocols are reviewed.
Pruritus in chronic liver disease: mechanisms and treatment.
Bergasa NV. Curr Gastroenterol Rep 2004; 6: 10–16.
This is an excellent and succinct review of cholestatic pruritus. It presents what is known regarding the pathophysiology of itch and cholestasis, and it discusses targeted treatment strategies in cholestatic disorders.
Neuropathic itch arises as a consequence of pathology at one or more points along the afferent (sensory) pathway of the peripheral or central nervous system. Brachioradial pruritus (BRP) and notalgia paresthetica (NP) are the two best examples of the isolated sensory peripheral neuropathies seen by dermatologists. Workers in this field believe that dorsal spinal nerve radiculopathy, usually secondary to degenerative disease of cervical and thoracic vertebral bodies, lead to persistent itching, paresthesia, hypesthesia, or burning/stinging pain. The involved areas may also be hyperpigmented and excoriated. These forms of localized pruritus may go undiagnosed for quite some time. By the time patients fail to respond to various treatments and obtain a dermatology referral, the itch has often been going on for months and may have become generalized, with secondary changes that may be mistaken for a primary dermatosis. Several investigators have observed patients in whom brachioradial pruritus appears to have triggered generalization to areas beyond those normally involved in classic BRP.
Repeated application of capsaicin cream, which depletes axonal stores of substance P, may be an effective approach to the treatment of localized areas of neuropathic pain or itch. While evidence for the use of gabapentin in the treatment of BRP and NP is mostly anecdotal to date, it is being used increasingly with success for more widespread or otherwise recalcitrant neuropathic dysethesias, including itch and pain. Doses as high as 2400 mg or more daily in divided doses, as tolerated, may be necessary. Pregabalin, an analog of gabapentin, has also been effective in the treatment of neuropathic pain syndromes (such as post-herpetic neuralgia and diabetic neuropathy); there is evidence that it may be effective in treating neuropathic itch as well (e.g., BRP and post-herpetic pruritus).
Brachioradial pruritus as a result of cervical spine pathology: the results of a magnetic resonance tomography study.
Marziniak M, Phan NQ, Raap U, Siepmann D, Schürmeyer-Horst F, Pogatzki-Zahn E, Niederstadt T, Ständer S. J Am Acad Dermatol 2011; 65: 756–62.
Brachioradial pruritus: a trigger for generalization of itch.
Kwatra SG, Ständer S, Bernhard JD, Weisshar E, Yosipovitch G. J Am Acad Dermatol 2013; 68: 870–3.
A classic study, providing the strongest data yet that BRP may result from cervical nerve compression or from degenerative changes of the cervical spine.
Successful treatment of notalgia paresthetica with topical capsaicin: vehicle-controlled, double-blind, crossover study.
Wallengren J, Klinker M. J Am Acad Dermatol 1995; 32: 287–9.
In this 10-week study, 20 patients with notalgia paresthetica were treated with capsaicin cream or placebo five times daily for 1 week and then three times daily for 3 weeks. Treatment was stopped for 2 weeks prior to all patients using capsaicin cream on the same schedule as before. Seventy percent of patients treated with capsaicin cream had improved symptoms compared to only 30% on placebo. Pruritus did not intensify during the washout period in patients who received capsaicin cream in the first 4 weeks.
Solar (brachioradial) pruritus – response to capsaicin cream.
Knight TE, Hayashi T. Int J Dermatol 1994; 33: 206–9.
In this open-label trial of capsaicin cream, 10 of 13 patients completing the study found significant relief (itching much improved or gone) from itch on the treated arm after 3 weeks compared to the untreated control arm.
Gabapentin treatment for notalgia paresthetica, a common isolated peripheral sensory neuropathy.
Loosemore MP, Bordeaux JS, Bernhard JD. J Eur Acad Dermatol Venereol 2007; 21: 1440–1.
An 82-year-old man with NP and BRP was treated with gabapentin 600 mg at night with resolution of symptoms. Symptoms recurred when gabapentin was stopped and then resolved with re-initiation of the medication.
Brachioradial pruritus: response to treatment with gabapentin.
Winhoven SM, Coulson IH, Bottomley WW. Br J Dermatol 2004; 150: 786–7.
In this report, two patients with brachioradial pruritus resistant to other therapies responded to gabapentin 300 mg three times daily.
Brachioradial pruritus: report of a new case responding to gabapentin.
Kanitakis J. Eur J Dermatol 2006; 16: 311–12.
A 54-year-old man with BRP noted significant (90%) improvement in pruritus with gabapentin 600 mg three times daily and the use of an antipruritic cream containing 8% calamine and essential fatty acids. He initially had diarrhea and sleepiness at this dose. Pruritus returned with discontinuation of gabapentin and again resolved with its re-initiation.
Gabapentin treatment for brachioradial pruritus.
Bueller HA, Bernhard JD, Dubroff LM. J Eur Acad Dermatol Venereol 1999; 13: 227–8.
Pregabalin in the treatment of chronic pruritus.
Ehrchen J, Ständer S. J Am Acad Dermatol 2008; 58: S36–7.
Cholestasis, a reduction of bile flow, results from a variety of hepatic, as well as extrahepatic, diseases. While the pathophysiological link between cholestasis and pruritus is not fully understood, an increasing body of evidence supports the proposition that it occurs as a consequence of increased levels of endogenous opioids. Pruritus of cholestasis is typically widespread, characteristically involves the palms and soles, and may be accompanied by jaundice. Therapeutic interventions have focused on the removal of presumed pruritogens from the circulation (through the use of ursodeoxycholic acid, cholestyramine), induction of hepatic enzymes (rifampin), antagonism of endogenous opioid receptors (naltrexone, nalaxone, nalmefene), modulation of serotonin neurotransmission (sertraline), activation of cannabinoid receptors (dronabinol), and clearing water soluble and protein bound pruritogens through albumin-based dialysis (Molecular Adsorbent Recycling System, Prometheus®). Ultraviolet B (UVB) phototherapy and parenteral lidocaine are further therapeutic considerations.
The itch of liver disease.
Bergasa NV. Semin Cutan Med Surg 2011; 30: 93–8.
Update on the treatment of the pruritus of cholestasis.
Bergasa NV. Clin Liver Dis 2008; 12: 219–34.
Two relevant discussions on pruritus of cholestasis, its mechanism and endogenous mediators, as well as the potential role of a behavioral component to disease manifestation.
Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials.
Khurana S, Singh P. Liver Int 2006; 26: 943–8.
This meta-analysis includes five prospective randomized controlled trials with 61 patients who had pruritus associated with chronic liver disease. Complete or partial resolution of symptoms occurred in 77% of patients taking rifampin 300–600 mg daily.
The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus.
Tandon P, Rowe BH, Vandermeer B, Bain VG. Am J Gastroenterol 2007; 102: 1528–36.
In this review of 12 randomized controlled trials, both rifampin and opioid antagonists significantly reduced cholestasis associated pruritus. There was insufficient data to assess the efficacy of cholestyramine.
Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study.
Terg R, Coronel E, Sordá J, Muñoz AE, Findor J. J Hepatol 2002; 37: 717–22.
In this double-blind randomized placebo controlled crossover trial of 20 patients with cholestasis associated pruritus, nine of 20 patients taking naltrexone 50 mg daily experienced a greater than 50% reduction in symptoms relative to baseline, including five whose pruritus disappeared completely. Adverse effects included a short lived opioid withdrawal like phenomenon.
Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study.
Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. J Am Acad Dermatol 1999; 41(3 Pt 1): 431–4.
In a randomized double-blind placebo controlled study with pruritus associated with chronic liver disease, nalmefene therapy was associated with a 75% reduction in the mean hourly scratching activity and a decrease in the mean visual analog scale (VAS) score of the perception of pruritus in all eight patients.
Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial.
Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, et al. Ann Intern Med 1995; 123: 161–7.
In this double-blind placebo-controlled crossover trial in 29 patients with liver disease, nalaxone infusions resulted in significantly improved VAS scores and hourly scratching activity compared to placebo.
Treatment of Skin Disease Comprehensive Therapeutic Strategies 4e
WhatsApp us